Published in Cancer Weekly, July 6th, 2004
"Ten patients with malignant melanoma and phototoxic reactions under dacarbazine or 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (DTIC) chemotherapy were investigated," scientists in Germany report.
"All patients available for testing showed increased ultraviolet A-sensitivity (n=5); patch testing revealed no type IV allergies (n=6). In 5 patients intravenous DTIC was replaced by oral temozolomide, and no photoxicity occurred," wrote R. Treudler and colleagues, University of Berlin, School of Medicine.
The researchers concluded:...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.